Palantir’s NHS data deal unravels amid doubts, stock slump

By mid-2026, independent investigations led by Foxglove revealed a striking disconnect between Palantir’s promises and actual clinical outcomes within the NHS. Nearly one third of trusts using Palantir’s Federated Data Platform (FDP) for scheduling patient operations reported performing 9,073 fewer operations post-adoption, directly challenging claims of increased surgical volumes. Foxglove’s Tim Squirrell criticized the NHS and Palantir for withholding transparent, trust-level data and comparative figures from non-users, making it difficult to verify the platform’s true impact. This lack of openness, combined with the uneven distribution of benefits—where improvements were concentrated in a handful of trusts—suggests that Palantir’s FDP is masking a far less positive reality across the NHS.

Further scrutiny in July 2026 by the Health Foundation and Financial Times cast doubt on Palantir’s claims of reducing hospital discharge delays, a key operational metric touted by NHS England. Their analysis found no meaningful difference in discharge delays between trusts using Palantir’s £330 million patient-tracking tool and those not using it, with nearly half of trusts showing implausible sudden drops in delays attributed to data entry errors rather than genuine improvements. This revelation, coupled with the observation that many trusts treated fewer patients after implementing the platform, underscores a troubling gap between the software’s promises and the harsh realities of clinical throughput and operational efficiency.

Healthcare economists emphasize that Palantir’s digital tools, while capable of optimizing existing workflows, cannot overcome fundamental systemic challenges such as bed shortages and social care deficits that drive 77 percent of discharge delays. This limitation highlights a critical flaw in the platform’s operational impact: no amount of data sophistication can substitute for the physical resources and workforce necessary to improve patient flow. The persistent underperformance of trusts using Palantir’s FDP thus reflects broader structural issues in the NHS that digital innovation alone cannot resolve.

By mid-2026, UK parliamentary committees and regulatory bodies had intensified scrutiny of Palantir's NHS Federated Data Platform (FDP), urging the government to consider activating a break clause in the contract to reduce reliance on the US firm. MPs expressed serious mistrust, highlighting that NHS England could not definitively link the platform to improved patient outcomes, with some trusts reportedly outperforming those using Palantir's tools. This skepticism was compounded by demands for clearer, comparative data, as campaign groups like Foxglove challenged the NHS's published benefits, arguing that improvements in some hospitals were offset by declines in others, thereby questioning the platform's overall efficacy.

Regulatory pressure culminated with the UK Office for Statistics Regulation mandating that government communications about Palantir's FDP be accurate and transparent, particularly criticizing claims such as 'over 100,000 additional NHS operations' for lacking causal evidence and uneven distribution. Despite calls from nonprofits like Foxglove for ministers to withdraw misleading figures, officials persisted in citing them without qualification, prompting watchdog demands for corrected records to ensure public discourse is grounded in reliable evidence rather than promotional spin.

Further investigations, including a Health Foundation study and a Financial Times probe, revealed profound data anomalies and no meaningful reduction in discharge delays attributable to Palantir's platform, intensifying calls for independent audits and transparency. Nearly 30 percent of trusts using the FDP reportedly operated with fewer patients post-implementation, fueling parliamentary and public pressure to reconsider the contract. The Health and Social Care Committee formally requested information on plans to appoint a new supplier by March 2027, signaling a strong institutional push towards contract termination or replacement leveraging the existing break clause.

By mid-2026, significant concerns had crystallized around Palantir's role in managing NHS patient data, with campaigners like Medact and watchdogs such as Foxglove highlighting serious threats to patient privacy. The lack of transparent data sharing by both NHS England and Palantir regarding the Federated Data Platform’s (FDP) actual impact has stymied effective public and parliamentary scrutiny, deepening mistrust about data privacy and security assurances. Foxglove’s head of strategy, Tim Squirrell, criticized the government’s reliance on what he termed 'ropey evidence' to justify extending contracts with a US tech giant in such a critical public service, underscoring fears that opaque operations undermine accountability and patient trust.

This apprehension intensified into political pressure by July 2026, as MPs on the Health and Social Care Committee publicly urged the government to find a replacement for Palantir’s FDP, citing 'serious mistrust' that could deter patients from sharing vital medical information. The committee’s call to end the £330 million contract reflects broader unease not only about data security and privacy but also about the dominance of a US technology firm in handling sensitive NHS data. Political figures like Andy Burnham echoed these concerns, signaling a growing consensus that the involvement of an American tech giant in the UK’s public healthcare infrastructure may compromise data control and public confidence.

Palantir Technologies faced a notable 6% stock decline to $125.03 on July 23, 2026, primarily driven by heightened regulatory scrutiny over its NHS Federated Data Platform contract and the emergence of a free open-source competitor, World Monitor. This dual pressure not only cast doubts on Palantir’s compliance with UK Office for Statistics Regulation standards but also underscored the strategic vulnerabilities in its UK healthcare data market foothold, signaling potential risks to future expansion and contract performance.

Compounding Palantir’s challenges, the company’s bearish stock trend was exacerbated by a broader weak technology sector and declining U.S. stock futures, creating a tough market environment as it approached its Q2 earnings report on August 3. Despite these headwinds and investor caution fueled by NHS contract uncertainties, Palantir demonstrated robust growth earlier in 2026, with U.S. commercial revenue surging 71% in Q1, highlighting a complex dynamic between strong underlying business performance and external market and regulatory pressures.